Frequency, etiologies, risk factors, and sequelae of falls among patients with brain metastases: A population- and institutional-level analysis.
bleeding
brain metastases
falls
hospitalization
population
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
Falls in patients with cancer harbor potential for serious sequelae. Patients with brain metastases (BrM) may be especially susceptible to falls but supporting investigations are lacking. We assessed the frequency, etiologies, risk factors, and sequelae of falls in patients with BrM using 2 data sources. We identified 42 648 and 111 patients with BrM utilizing Surveillance, Epidemiology, and End Results (SEER)-Medicare data (2008-2016) and Brigham and Women's Hospital/Dana-Farber Cancer Institute (BWH/DFCI) institutional data (2015), respectively, and characterized falls in these populations. Among SEER-Medicare patients, 10 267 (24.1%) experienced a fall that prompted medical evaluation, with cumulative incidences at 3, 6, and 12 months of 18.0%, 24.3%, and 34.1%, respectively. On multivariable Fine/Gray's regression, older age (≥81 or 76-80 vs 66-70 years, hazard ratio [HR] 1.18 [95% CI, 1.11-1.25], Falls are common among patients with BrM, especially older/sicker patients, and can have deleterious consequences. Risk-reduction measures, such as home safety checks, physical therapy, and medication optimization, should be considered in this population.
Sections du résumé
Background
UNASSIGNED
Falls in patients with cancer harbor potential for serious sequelae. Patients with brain metastases (BrM) may be especially susceptible to falls but supporting investigations are lacking. We assessed the frequency, etiologies, risk factors, and sequelae of falls in patients with BrM using 2 data sources.
Methods
UNASSIGNED
We identified 42 648 and 111 patients with BrM utilizing Surveillance, Epidemiology, and End Results (SEER)-Medicare data (2008-2016) and Brigham and Women's Hospital/Dana-Farber Cancer Institute (BWH/DFCI) institutional data (2015), respectively, and characterized falls in these populations.
Results
UNASSIGNED
Among SEER-Medicare patients, 10 267 (24.1%) experienced a fall that prompted medical evaluation, with cumulative incidences at 3, 6, and 12 months of 18.0%, 24.3%, and 34.1%, respectively. On multivariable Fine/Gray's regression, older age (≥81 or 76-80 vs 66-70 years, hazard ratio [HR] 1.18 [95% CI, 1.11-1.25],
Conclusions
UNASSIGNED
Falls are common among patients with BrM, especially older/sicker patients, and can have deleterious consequences. Risk-reduction measures, such as home safety checks, physical therapy, and medication optimization, should be considered in this population.
Identifiants
pubmed: 35371522
doi: 10.1093/nop/npab061
pii: npab061
pmc: PMC8965072
doi:
Types de publication
Journal Article
Langues
eng
Pagination
114-122Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Age Ageing. 1997 May;26(3):189-93
pubmed: 9223714
J Geriatr Oncol. 2015 Jan;6(1):70-83
pubmed: 25454770
Neuro Oncol. 2020 Sep 29;22(9):1339-1347
pubmed: 32149345
J Geriatr Oncol. 2017 Jul;8(4):255-261
pubmed: 28602712
J Clin Oncol. 2007 May 10;25(14):1824-31
pubmed: 17488980
Neuro Oncol. 2020 Apr 15;22(4):575-576
pubmed: 31904086
Drugs. 1978 Sep;16(3):238-55
pubmed: 209958
Curr Oncol Rep. 2012 Feb;14(1):48-54
pubmed: 22012633
Cochrane Database Syst Rev. 2018 Oct 15;10:CD011687
pubmed: 30320433
J Bone Miner Res. 2014 Nov;29(11):2520-6
pubmed: 24771492
Nat Rev Dis Primers. 2019 Jan 17;5(1):5
pubmed: 30655533
J Geriatr Oncol. 2019 Jan;10(1):105-111
pubmed: 30170991
J Clin Oncol. 2012 Jun 10;30(17):2128-33
pubmed: 22585687
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Br J Clin Pharmacol. 2006 Feb;61(2):218-23
pubmed: 16433876
Support Care Cancer. 2012 Aug;20(8):1589-99
pubmed: 22526151
Ann Emerg Med. 2014 Sep;64(3):299-313
pubmed: 24721718
J Adv Nurs. 2006 Mar;53(5):524-33
pubmed: 16499673
N Engl J Med. 2003 Jan 2;348(1):42-9
pubmed: 12510042
J Clin Oncol. 2010 Oct 10;28(29):4457-64
pubmed: 20837950
Clin Interv Aging. 2019 Apr 24;14:701-719
pubmed: 31190764
Ther Adv Drug Saf. 2013 Aug;4(4):147-54
pubmed: 25114778
Cardiol Ther. 2013 Dec;2(2):135-49
pubmed: 25135392
J Neurooncol. 2009 Dec;95(3):427-431
pubmed: 19562256
Maturitas. 2013 May;75(1):51-61
pubmed: 23523272
Arch Intern Med. 2009 Nov 23;169(21):1952-60
pubmed: 19933955